Risk of CIN3 drops with negative HPV, cytology co-tests

November 28, 2017

(HealthDay)—The five-year risks of cervical intraepithelial neoplasia grade 3 (CIN3), adenocarcinoma in situ, and cervical cancer (≥CIN3) decrease after each successive negative human papillomavirus (HPV) and cytology co-testing, according to a study published online Nov. 27 in the Annals of Internal Medicine.

Philip E. Castle, Ph.D., M.P.H., from the Albert Einstein College of Medicine in Bronx, N.Y., and colleagues conducted an observational cohort study involving 990,013 women who had one or more co-tests from 2003 to 2014. The authors examined the three- and five-year cumulative detection of ≥CIN3.

The researchers observed a decrease in five-year ≥CIN3 risks after each successive negative co-test screening round (0.098, 0.052, and 0.035 percent for first, second, and third co-test, respectively). Regardless of the cytology result, five-year ≥CIN3 risks for an HPV-negative co-test nearly matched the performance of a negative co-test for each successive round of screening (0.114, 0.061, and 0041 percent, respectively). For the cytology-negative co-test, ≥CIN3 risks also decreased with each successive round, regardless of the HPV result, but the three-year risks were as high as five-year risks after an HPV-negative co-test (0.199, 0.065, and 0.043 percent, respectively). After the second negative co-test, no interval cases were diagnosed.

"After one or more negative cervical co-tests (or HPV tests), longer intervals (every five years or more) might be feasible and safe," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further: Low incidence of cervical cancer, CIN3+ for HPV-negative women

More information: Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Low incidence of cervical cancer, CIN3+ for HPV-negative women

October 7, 2016
(HealthDay)—Human papillomavirus (HPV)-negative women have low long-term incidence of cervical cancer and cervical intraepithelial neoplasia (CIN) grade 3 or worse (CIN3+), which supports an extension of the cervical screening ...

Risk of noncervical anogenital cancer up with history of CIN2/3

July 6, 2016
(HealthDay)—Women with a history of cervical intraepithelial neoplasia (CIN)2 or CIN3 have increased risks of subsequent development of anal, vulvar, and vaginal cancers, according to a study published online June 29 in ...

HIV-seropositive CIN3+ patients have lower HPV16 prevalence

March 16, 2016
(HealthDay)—HIV-seropositive women with cervical intraepithelial neoplasia (CIN) grade ≥3 (CIN3+) are less likely to have human papillomavirus (HPV) 16, according to a study published in the March issue of the American ...

Screening for cervical abnormalities in women offered HPV vaccination

September 19, 2017
Human papillomavirus (HPV) testing detects a higher number of precancerous cervical lesions than cytology-based Pap smears in a female population including a proportion offered HPV vaccination, according to a new study published ...

HPV testing prevents more invasive cervical cancers than cytology

January 18, 2010
Human papillomavirus (HPV) DNA testing prevents more invasive cervical cancer compared to cytology screening alone by detecting persistent high-grade lesions (which lead to cervical cancer) at an earlier time. As such, HPV ...

HPV testing followed by smear could improve cervical screening

February 29, 2012
(Medical Xpress) -- Testing for the human papillomavirus (HPV) – a virus most women will encounter at some point in their lives – followed by a smear test if they are HPV positive, provides the most effective approach ...

Recommended for you

Mutant cells colonize our tissues over our lifetime

October 18, 2018
By the time we reach middle age, more than half of the oesophagus in healthy people has been taken over by cells carrying mutations in cancer genes, scientists have uncovered. By studying normal oesophagus tissue, scientists ...

Study involving hundreds of patient samples may reveal new treatment options of leukemia

October 17, 2018
After more than five years and 672 patient samples, an OHSU research team has published the largest cancer dataset of its kind for a form of leukemia. The study, "Functional Genomic Landscape of Acute Myeloid Leukemia", published ...

A 150-year-old drug might improve radiation therapy for cancer

October 17, 2018
A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more sensitive to radiation therapy, according to a recent study led by researchers at The Ohio State University Comprehensive Cancer ...

Loss of protein p53 helps cancer cells multiply in 'unfavourable' conditions

October 17, 2018
Researchers have discovered a novel consequence of loss of the tumour protein p53 that promotes cancer development, according to new findings in eLife.

New method uses just a drop of blood to monitor lung cancer treatment

October 17, 2018
Dr. Tasuku Honjo won the 2018 Nobel Prize in physiology or medicine for discovering the immune T-cell protein PD-1. This discovery led to a set of anti-cancer medications called checkpoint inhibitors, one of the first of ...

Researcher fighting breast cancer with light therapy

October 17, 2018
When treatment is working for a patient who is fighting cancer, the light at the end of the tunnel is easier to see.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.